CytoDyn Company Profile (NASDAQ:CYDY)

About CytoDyn (NASDAQ:CYDY)

CytoDyn logoCytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CYDY
  • CUSIP: N/A
  • Web: www.cytodyn.com
Capitalization:
  • Market Cap: $111.52 million
  • Outstanding Shares: 152,763,000
Average Prices:
  • 50 Day Moving Avg: $0.71
  • 200 Day Moving Avg: $0.66
  • 52 Week Range: $0.46 - $1.17
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.29
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($0.01) per share
  • Price / Book: -73.00
Profitability:
  • EBIDTA: ($26,960,000.00)
  • Return on Equity: -602.94%
  • Return on Assets: -213.85%
Misc:
  • Average Volume: 178,789 shs.
 
Frequently Asked Questions for CytoDyn (NASDAQ:CYDY)

What is CytoDyn's stock symbol?

CytoDyn trades on the NASDAQ under the ticker symbol "CYDY."

How were CytoDyn's earnings last quarter?

CytoDyn Inc (NASDAQ:CYDY) posted its quarterly earnings data on Wednesday, October, 12th. The company reported ($0.04) EPS for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.01. View CytoDyn's Earnings History.

Where is CytoDyn's stock going? Where will CytoDyn's stock price be in 2017?

2 brokerages have issued 12-month target prices for CytoDyn's shares. Their forecasts range from $1.60 to $2.00. On average, they expect CytoDyn's stock price to reach $1.80 in the next year. View Analyst Ratings for CytoDyn.

Who are some of CytoDyn's key competitors?

Who are CytoDyn's key executives?

CytoDyn's management team includes the folowing people:

  • Anthony D. Caracciolo, Independent Chairman of the Board
  • Nader Z. Pourhassan Ph.D., President, Chief Executive Officer, Director
  • Michael D. Mulholland, Chief Financial Officer, Treasurer, Corporate Secretary
  • Denis R. Burger Ph.D., Director
  • Carl C. Dockery, Director
  • Gregory A. Gould CPA, Independent Director
  • A. Bruce Montgomery M.D., Independent Director
  • Jordan G. Naydenov, Independent Director

How do I buy CytoDyn stock?

Shares of CytoDyn can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytoDyn's stock price today?

One share of CytoDyn stock can currently be purchased for approximately $0.73.


MarketBeat Community Rating for CytoDyn (NASDAQ CYDY)
Community Ranking:  2.3 out of 5 ( )
Outperform Votes:  19 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  42
MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CytoDyn (NASDAQ:CYDY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $1.80 (146.58% upside)

Analysts' Ratings History for CytoDyn (NASDAQ:CYDY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/14/2016HC WainwrightSet Price TargetBuy$2.00N/AView Rating Details
10/6/2016Rodman & RenshawInitiated CoverageBuy$1.60N/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for CytoDyn (NASDAQ:CYDY)
Earnings by Quarter for CytoDyn (NASDAQ:CYDY)
Earnings History by Quarter for CytoDyn (NASDAQ CYDY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/12/2016Q1($0.05)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CytoDyn (NASDAQ:CYDY)
Current Year EPS Consensus Estimate: $-0.17 EPS
Next Year EPS Consensus Estimate: $-0.17 EPS

Dividends

Dividend History for CytoDyn (NASDAQ:CYDY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CytoDyn (NASDAQ:CYDY)
Insider Trades by Quarter for CytoDyn (NASDAQ:CYDY)
Insider Trades by Quarter for CytoDyn (NASDAQ:CYDY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/21/2016Nader PourhassanInsiderBuy15,000$0.66$9,900.00View SEC Filing  
10/17/2016Michael D MulhollandCFOBuy11,000$0.66$7,260.00View SEC Filing  
10/30/2014Anthony CaraccioloDirectorBuy26,000$0.72$18,720.00View SEC Filing  
10/15/2014Michael D MulhollandCFOBuy2,500$0.79$1,975.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CytoDyn (NASDAQ:CYDY)
Latest Headlines for CytoDyn (NASDAQ:CYDY)
Source:
DateHeadline
americanbankingnews.com logoCytoDyn Inc (NASDAQ:CYDY) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - July 19 at 9:50 PM
americanbankingnews.com logo Analysts Set $2.88 Price Target for CytoDyn Inc (NASDAQ:CYDY)
www.americanbankingnews.com - July 19 at 6:28 PM
americanbankingnews.com logo Analysts Expect CytoDyn Inc (CYDY) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - July 7 at 8:22 PM
americanbankingnews.com logoZacks: CytoDyn Inc (CYDY) Given $2.88 Consensus Target Price by Brokerages
www.americanbankingnews.com - June 21 at 4:38 PM
americanbankingnews.com logoZacks: Analysts Expect CytoDyn Inc (CYDY) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - June 13 at 8:10 PM
finance.yahoo.com logoCytoDyn to Present at the 7th Annual LD Micro Invitational on June 6
finance.yahoo.com - June 2 at 6:08 PM
feeds.benzinga.com logoCytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017
feeds.benzinga.com - June 1 at 6:53 AM
americanbankingnews.com logoZacks: CytoDyn Inc (CYDY) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 30 at 4:48 PM
americanbankingnews.com logoZacks Investment Research Downgrades CytoDyn Inc (CYDY) to Sell
www.americanbankingnews.com - May 24 at 7:02 PM
globenewswire.com logoCytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease - GlobeNewswire (press release)
globenewswire.com - May 17 at 11:18 AM
finance.yahoo.com logoCytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease
finance.yahoo.com - May 17 at 11:18 AM
americanbankingnews.com logoZacks: Analysts Expect CytoDyn Inc (CYDY) to Post -$0.04 EPS
www.americanbankingnews.com - May 17 at 8:56 AM
americanbankingnews.com logoZacks: CytoDyn Inc (CYDY) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 11 at 9:18 AM
americanbankingnews.com logoZacks: Analysts Anticipate CytoDyn Inc (CYDY) to Post -$0.04 Earnings Per Share
www.americanbankingnews.com - April 26 at 11:42 AM
americanbankingnews.com logoZacks: CytoDyn Inc (CYDY) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - April 25 at 10:20 AM
seekingalpha.com logoCytoDyn's (CYDY) CEO Nader Pourhassan Hosts Investment Community Conference Call (Transcript)
seekingalpha.com - April 19 at 12:36 PM
finance.yahoo.com logoPotential for CytoDyn’s PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA
finance.yahoo.com - April 17 at 11:55 AM
finance.yahoo.com logoReminder: CytoDyn to Hold Investment Community Conference Call April 18, 2017
finance.yahoo.com - April 13 at 4:36 PM
finance.yahoo.com logoCytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors
finance.yahoo.com - April 11 at 12:58 PM
americanbankingnews.com logoZacks: CytoDyn Inc (CYDY) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - April 10 at 8:31 AM
globenewswire.com logoCytoDyn Announces Investment Community Conference Call for April 18, 2017 - GlobeNewswire (press release)
globenewswire.com - April 8 at 10:15 AM
prnewswire.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating CytoDyn Inc. for Potential Breaches Of Fiduciary ... - PR Newswire (press release)
www.prnewswire.com - April 3 at 5:02 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating CytoDyn Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 3 at 5:02 PM
biz.yahoo.com logoCYTODYN INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 30 at 5:02 PM
americanbankingnews.com logoZacks: CytoDyn Inc (CYDY) Receives Consensus Rating of "" from Brokerages
www.americanbankingnews.com - March 24 at 12:40 PM
finance.yahoo.com logoData Presented at CROI Show CytoDyn’s Pro 140 as a Single Agent Provided Maximal Virologic Suppression in HIV Patients for Nearly Two Years
finance.yahoo.com - February 16 at 1:46 PM
feeds.benzinga.com logoData Presented at CROI Show CytoDyn's Pro 140 as a Single Agent Provided Maximal Virologic Suppression in HIV Patients for Nearly Two Years
feeds.benzinga.com - February 16 at 12:26 AM
finance.yahoo.com logoCytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman
finance.yahoo.com - January 30 at 10:27 AM
finance.yahoo.com logoCytoDyn Reports Treatment of First Several Patients With PRO 140 in Its Phase 3 Monotherapy Trial for HIV
finance.yahoo.com - December 12 at 12:09 PM
biz.yahoo.com logoCYTODYN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - December 12 at 12:09 PM

Social

Chart

CytoDyn (CYDY) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff